February 24, 2026
Promatix’s lead asset ADC for colorectal cancer has positive preclinical data
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.